Extended review for Acetadote supplement hits Cumberland shares
This article was originally published in Scrip
Executive Summary
Shares in Cumberland Pharmaceuticals, which have languished since the company broke the deadlock in a recession-hit pharmaceutical sector by raising around $75 million net in an IPO last August, took a further battering yesterday after Cumberland announced a delay in the FDA's review of a new indication for Acetadote (acetylcysteine) injection.